HEALTH PROFESSIONAL · SOURCE READING
H3.3 (H3F3A) variant at G34
Source: Childhood Cancer Genomics (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 30, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
The H3.3 G34 subtype arises from H3.3 glycine 34 to arginine/valine (G34R/V) variants.[36,37] This subtype presents in older children and young adults (median age, 14–18 years) and arises exclusively in the cerebral cortex.[36,37] H3.3 G34 cases commonly have variants in TP53 and ATRX (95% and 84% of cases, respectively, in one large series) and show widespread hypomethylation across the whole genome. In a series of 95 patients with the H3.3 G34 subtype, 44% of patients also had a variant in PDGFRA at the time of diagnosis, and 81% of patients had PDGFRA variants observed at relapse.[47]
Patients with H3F3A variants are at high risk of treatment failure,[48] but the prognosis is not as poor as that of patients with histone 3.1 or 3.3 K27M variants.[37] O-6-methylguanine-DNA methyltransferase (MGMT) methylation is observed in approximately two-thirds of cases, and aside from the IDH1-altered subtype (see below), the H3.3 G34 subtype is the only pediatric high-grade glioma subtype that demonstrates MGMT methylation rates exceeding 20%.[10]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle